182 related articles for article (PubMed ID: 28578786)
1. Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era.
Uhm JH; Porter AB
Mayo Clin Proc; 2017 Jun; 92(6):995-1004. PubMed ID: 28578786
[TBL] [Abstract][Full Text] [Related]
2. Novel chemotherapeutics and other therapies for treating high-grade glioma.
Kang JH; Adamson C
Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy approaches for malignant glioma from 2007 to 2009.
Johnson LA; Sampson JH
Curr Neurol Neurosci Rep; 2010 Jul; 10(4):259-66. PubMed ID: 20424975
[TBL] [Abstract][Full Text] [Related]
4. T11TS immunotherapy repairs PI3K-AKT signaling in T-cells: Clues toward enhanced T-cell survival in rat glioma model.
Chaudhuri S; Singh MK; Bhattacharya D; Datta A; Hazra I; Mondal S; Faruk Sk Md O; Ronsard L; Ghosh TK; Chaudhuri S
J Cell Physiol; 2018 Feb; 233(2):759-770. PubMed ID: 28608562
[TBL] [Abstract][Full Text] [Related]
5. Personalized medicine in neuro-oncology.
Levin VA
CNS Oncol; 2016; 5(2):55-8. PubMed ID: 26997307
[No Abstract] [Full Text] [Related]
6. Immunobiology and immunotherapeutic targeting of glioma stem cells.
Madany M; Thomas TM; Edwards L; Yu JS
Adv Exp Med Biol; 2015; 853():139-66. PubMed ID: 25895711
[TBL] [Abstract][Full Text] [Related]
7. Concepts for Immunotherapies in Gliomas.
Platten M; Reardon DA
Semin Neurol; 2018 Feb; 38(1):62-72. PubMed ID: 29548053
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes.
Qi Y; Liu B; Sun Q; Xiong X; Chen Q
Front Immunol; 2020; 11():578877. PubMed ID: 33329549
[TBL] [Abstract][Full Text] [Related]
9. Search for More Effective Chemotherapeutic Regimens for Gliomas: Challenges and Hopes.
Hu J; Kesari S
Prog Neurol Surg; 2018; 31():200-209. PubMed ID: 29393187
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of gliomas: potential therapeutic implications.
Alentorn A; Duran-Peña A; Pingle SC; Piccioni DE; Idbaih A; Kesari S
Expert Rev Anticancer Ther; 2015; 15(8):955-62. PubMed ID: 26118895
[TBL] [Abstract][Full Text] [Related]
11. [Dendritic cell therapy for malignant glioma].
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
[TBL] [Abstract][Full Text] [Related]
13. Cellular immunity in the treatment of brain tumors.
Wheeler CJ; Yu JS; Black KL
Clin Neurosurg; 2004; 51():132-9. PubMed ID: 15571138
[No Abstract] [Full Text] [Related]
14. Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.
Zhang C; Li J; Wang H; Song SW
Oncotarget; 2016 Nov; 7(45):73971-73983. PubMed ID: 27738332
[TBL] [Abstract][Full Text] [Related]
15. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
16. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of brain tumors.
Sawamura Y; De Tribolet N
J Neurosurg Sci; 1990; 34(3-4):265-78. PubMed ID: 2098505
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for glioma: getting closer to the clinical arena?
Finocchiaro G; Pellegatta S
Curr Opin Neurol; 2011 Dec; 24(6):641-7. PubMed ID: 22027543
[TBL] [Abstract][Full Text] [Related]
19. An attempt to conceptualize the individual onco-functional balance: Why a standardized treatment is an illusion for diffuse low-grade glioma patients.
Mandonnet E; Duffau H
Crit Rev Oncol Hematol; 2018 Feb; 122():83-91. PubMed ID: 29458793
[TBL] [Abstract][Full Text] [Related]
20. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
